Search

Search Constraints

You searched for: Author/Creator Cheon, Jaekyung

Search Results

1. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. (February 2023)

3. Corrigendum to "Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO studyˮ [Eur J Canc 144 (2021) 341–350]. (May 2021)

4. Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway. (1st January 2021)

5. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. (29th November 2021)

6. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. (May 2020)

7. Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2‐negative metastatic breast cancer. Issue 4 (7th May 2021)

8. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. (February 2021)

9. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Issue 11 (November 2021)

10. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment. (23rd August 2022)